Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Med (OTCQB: ADIA) is enhancing IV therapy quality by having Lead Physician Dr. Brian Browning train APRNs and RNs in ultrasound-guided IV insertions using the Butterfly portable ultrasound device.
The program targets more precise, reliable, and comfortable IV access, especially for patients with difficult veins, and supports Adia Med’s regenerative and nutrient therapies, including stem cell, exosome, glutathione, and other precision wellness infusions.
Adia Nutrition (OTCQB: ADIA) has received State of Nevada approval to change its corporate name to Adia Med Inc.
The change reflects a focus on advanced medical and wellness solutions, including active clinical studies, a research pipeline at Adia Labs, and distribution of stem cell and exosome products. Trading symbol and CUSIP will remain unchanged, pending FINRA review.
Adia Nutrition (OTCQB: ADIA) launched wholly owned subsidiary ADIA Life LLC, headquartered in Florida, to centralize distribution of Adia Labs products and manage a nationwide distributor network.
The unit will streamline logistics and support future consumer programs in nutrition, fitness, mindset coaching and broader wellness solutions within the $4.5 trillion global wellness industry.
Adia Nutrition (OTCQB: ADIA) announced a nearly completed documentary featuring TNA Wrestling star Jeff Sciullo, known as Elias, highlighting his recovery from a severe tricep tendon tear.
The film follows his comeback after surgery and an AdiaVita stem cell and exosome infusion, showing accelerated healing and return to performance.
Adia Nutrition (OTCQB: ADIA) announced that an independent monthly-membership health care sharing ministry now accepts up to three stem cell treatments per client as an alternative to traditional insurance coverage.
The ministry serves over 250,000 members nationwide, expanding access to Adia’s regenerative therapies such as AdiaVita through affiliate clinics.
Adia Nutrition (OTCQB: ADIA) announced that subsidiary Adia Med is now recruiting for two ClinicalTrials.gov-listed studies: a Kidney Health Study (NCT07572890) and a Lower Back Pain Study (NCT07587047). Each plans to enroll up to 100 adults, evaluating proprietary AdiaVita stem cell and exosome therapy.
Participants pay $15,000 for the kidney study and $5,000 for the back pain study. According to Adia Med, full enrollment could generate $2,000,000 in study fees. A Georgia Autism Study has applied for ClinicalTrials.gov registration.
ADIA Nutrition (OTCQB: ADIA) reported 3rd party reviewed Q1 2026 results, showing significant year-over-year growth. Total revenue rose 146% to $176,275, driven by medical procedures and new biologics sales. Gross profit increased 381% to $67,577, while cash, deferred revenue, and total assets also grew.
ADIA Nutrition (OTCQB: ADIA) reported Institutional Review Board approval for all four planned clinical studies using its AdiaVita™ stem cell and exosome therapies.
The flagship kidney health study for Stage 2-4 chronic kidney disease is now registered on ClinicalTrials.gov and begins recruiting this week, while the Winter Park autism study has completed enrollment and is actively treating children.
Adia Nutrition (OTCQB: ADIA) announced IRB approval and a ClinicalTrials.gov submission on May 5, 2026 for a randomized, controlled study testing its AdiaVita stem cell and exosome therapy plus glutathione in adults with Stage 2–4 chronic kidney disease (CKD).
The trial will assess safety and track eGFR, serum creatinine, and inflammatory biomarkers; recruitment begins upon ClinicalTrials.gov acceptance.
Adia Nutrition (OTCQB: ADIA) reported IRB progress on three pivotal clinical studies: Lower Back Pain, Georgia Autism, and Kidney Study. The company received second-round IRB comments for the first two trials and first-round comments for the Kidney Study, and says final IRB approval is expected soon.
Adia plans to register all three studies on ClinicalTrials.gov and begin recruitment immediately after final IRB approval.